Gene therapy (AAV vector) · Gene replacement · developed by MeiraGTx, LLC
AAV2hAQP1 is an adeno-associated virus serotype 2 vector carrying the human aquaporin 1 gene, delivered into the parotid gland through Stensen's duct. It is intended to restore water transport in salivary gland cells, and it is studied in radiation-induced parotid gland hypofunction and xerostomia in patients with head and neck cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT04043104 | Phase 1 | Radiation-Induced Parotid Gland Hypofunction | Completed | MGTX |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Head and Neck CancerRadiation-Induced Parotid Gland HypofunctionXerostomia Due to Radiotherapy
Updated Oct 18, 2026. Something wrong or missing? Report it on the MGTX page.
See MGTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
MGTX catalysts and pipeline →